Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 476 followers
Latest posts
Last updated about 20 hours ago
Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan
about 8 hours ago
First RSV vaccine approved in Japan to help protect 50-59 year olds...
Company statement: GSK continues to show strong leadership in its Access to Medicines Index ranking
4 days ago
GSK is pleased to rank 2nd in the Access to Medicine Index...
Statement: GSK continues to show strong leadership in its Access to Medicines Index ranking
4 days ago
GSK is pleased to rank 2nd in the Access to Medicine Index...
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)
4 days ago
Primary endpoint met with a statistically significant improvement in itch over 24...
Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
9 days ago
Full data to be presented at 2024 American Society of Hematology Annual...
GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need
10 days ago
New data shows potential for sequential therapy of bepirovirsen after daplusiran/tomligisiran to...
New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers
11 days ago
GSK’s Your Cancer Is Our Challenge will raise awareness of barriers and...
GSK on track to deliver 2024 outlooks with further good progress made in R&D
24 days ago
Q3 2024 performance highlights
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
25 days ago
Agreement reinforces GSK’s portfolio in the treatment of lupus and underlying drivers...
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
30 days ago
Single dose of vaccine elicited robust immune response with acceptable safety profile...
GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease
about 1 month ago
GSK is investing more than £50 million in the CG-TIC to further...
ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024
about 1 month ago
Studies from OPERA and Trio cohorts provide further real-world evidence.